Immunome, Inc. (NASDAQ: IMNM), a biopharmaceutical company developing novel first-in-class antibody therapeutics targeting oncology and infectious diseases, announced the receipt of a clinical hold letter from the U.S. Food and Drug Administration (FDA) for its recently submitted Investigational New Drug (IND) for IMM-BCP-01, a three-antibody...
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company focused on creating novel therapeutics that use molecules to treat medical conditions with no approved cure. The Company’s lead product candidate is ZYESAMI™ (AVIPTADIL®) ZYESAMI™ (Aviptadil acetate), a synthetic Vasoactive Intestinal Peptide (VIP), which has...
Humanigen, Inc. (NASDAQ: HGEN) is a clinical-stage biopharmaceutical Company that is focused on creating a portfolio of monoclonal antibodies targeting immunology and immune-oncology disorders. The Company’s lead product candidate is lenzilumab, an anti-human granulocyte-macrophage colony-stimulating factor (“GM-CSF”) monoclonal antibody, formulated using the Company’s proprietary Humaneered®...
